Plasma connective tissue growth factor (CTGF) as a surrogate biomarker in asthma.

Plasma connective tissue growth factor (CTGF) as a surrogate biomarker in asthma. - Plasma CTGF in asthma.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000013081

Enrollment

Registered

2014-02-05

Start date

2009-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Classified as "controlled" under adequate treatment according to the GINA criteria of asthma control 2. Free from asthma symptoms, limitations of activities, exacerbation, and had no more than two rescue treatments a week even when required. 3. Received ICS, the mainstay of anti-inflammatory therapy in asthma, or ICS plus other antiasthmatic drugs for 1 year or more, with no change in dose within the previous 8 weeks.

Exclusion criteria

Exclusion criteria: 1) treatment with oral or intravenous corticosteroids in the previous 4 weeks, 2) having a smoking history more than 10 pack-years, 3) having other pulmonary diseases including chronic obstructive pulmonary disease.

Design outcomes

Primary

Measure	Time frame
Correlations between plasma CTGF levels and airway obstruction in patients with asthma.	—

Secondary

Measure	Time frame
Correlations between plasma CTGF levels and other clinical parameters in patients with asthma.	—

Countries

Japan

Contacts

Public ContactTomoyuki Fujisawa

Hamamatsu University School of Medicine Second division, Department of Internal Medicine

fujisawa@hama-med.ac.jp053-435-2261

Outcome results